Emboline has raised $20m to advance commercial activities associated with its device for reducing stroke and ischemic damage during structural heart procedures such as transcatheter aortic valve replacement (TAVR).
Originating from sole investor Trinity Capital, the latest funding tranche for the California-based company brings its total funds to date to around $93m.
Emboline’s Emboliner embolic protection system is designed to provide full cerebral and systemic embolic protection by capturing and removing embolic ‘debris’ released during transcatheter heart procedures.
This debris, primarily comprised of blood clots, fat globules, air bubbles, or other foreign materials, gets released in the course of TAVR procedures due to its manipulation by catheters, guidewires, or balloons. Research indicates that unless captured by embolic protection systems, there is the risk of this debris travelling to the brain and causing post-procedural stroke, with patients with heavily calcified arteries thought to be at the highest risk.
In the US, Boston Scientific’s SENTINEL is currently the only US Food and Drug Administration (FDA)-cleared cerebral embolic protection with a TAVR indication.
However, Emboline could soon offer competition. The company recently completed an investigational device exemption (IDE) clinical trial (NCT05684146) for Emboliner, the findings from which Emboline will present at the American College of Cardiology conference in New Orleans on 29 March.
Emboline’s CEO, Scott Russell, commented: "With the completion of our IDE clinical trial and regulatory submissions ahead, this financing positions us to prepare for commercial launch in the US and Europe later this year.”
Edwards Lifesciences is the dominant player in the TAVR and held a 60.3% share of the US TAVR market in 2025, as per a GlobalData market model. Meanwhile, further GlobalData analysis reveals that the broader transcatheter heart valve market is growing at a CAGR of 11.3% and is projected to reach a valuation of almost $27bn in 2035, up from $9.3bn in 2025.
During his presentation at the J.P. Morgan Healthcare Conference in January 2026, Edwards’ CEO Bernard Zovighian stated the company is aiming to achieve a 10% growth throughout 2026, with the broadening of TAVR treatment populations and ongoing evidence generation viewed as key growth drivers for the company across the year. This reflects both the size and importance that the TAVR market holds for many companies.
